semaglutide and tirzepatide equivalent doses SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide produced superior HbA1c reductions For the first time, tirzepatide

Characterized MC1R selectivity n.d

#Cipla #EliLilly #Yurpeak #Tirzepatide #DiabetesCare #ObesityManagement #Endocrinology #InternalMedicine #HealthcareProfessionals #PharmaNews #MedicalInnovation #CaringForLife #PatientCare #PharmaLeadership #HealthcareIndia Cipla has the rights to distribute and promote Yurpeak, a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity

Heres whats covered: Whats Not Included

DP designed and conducted the experiments

The main ingredients of both products are L-carnitine, zinc, niacin, biotin, and the branched-chain-amino-acids L-leucine, L-isoleucine and L-valine

Balanced Meals : Include a combination of protein diets, healthy fats, and complex carbohydrates in every meal